Skip to main content

Advertisement

Table 1 Clinical summary of patients

From: Expanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation

Patient/sex/age HCQ cumulative dose (g) Body mass index HCQ indication Follow-up after HCQ cessation (months) HCQ cessation VA Most recent VA Symptoms at HCQ cessation Symptoms at follow-up Progression after HCQ cessation?
E1/F/57 730 a Psoriatic arthritis 13 OD:20/20 OS:20/20 OD:20/20 OS:20/20 None None Yes (OCT, HVF)
E2/F/74 890 a SLE 13 OD:20/30 OS:20/40 OD:20/40 OS:20/40 Decreased near vision Decreased near vision Yes (OCT)
E3/F/69 584 51 RA 56 OD:20/25 OS:20/25 OD:20/30 OS:20/30 None None Yes (OCT, HCF)
E4/F/61 438 26 RA 12 OD:20/25 OS:20/25 OD:20/25 OS:20/25 Floaters None No
E5/F/65 949 17 RA 42 OD:20/20 OS:20/20 OD:20/20 OS:20/20 Floaters None Yes (OCT, HVF)
O1/F/48 2210 a SLE 18 OD:20/30 OS:20/40 OD:20/30 OS:20/30 None None Yes (OCT)
O2/F/65 4380 24 RA 36 OD:20/20 OS:20/20 OD:20/20 OS:20/20 Floaters Floaters Yes (OCT)
O3/F/62 1022 24 RA 42 OD:20/50 OS:20/60 OD:20/40 OS:20/50 Blurry vision Blurry vision No
O4/F/63 2482 a SLE 36 OD:20/25 OS:20/25 OD:20/25 OS:20/25 Floaters Flashes Yes (OCT)
O5/F/69 1550 a SLE 12 OD:20/25 OS:20/25 OD:20/25 OS:20/25 Glare Glare, floaters No
O6/F/67 1933 24 SLE 12 OD:20/25 OS:20/25 OD:20/25 OS:20/25 None None Yes (OCT)
O7/F/68 1048 26 RA 36 OD:20/20 OS:20/30 OD:20/30 OS:20/40 None Decreased near vision Yes (OCT, FP)
O8/F/75 2628 24 RA 12 OD:20/25 OS:20/25 OD:20/25 OS:20/25 None Decreased near vision Yes (OCT)
S1/F/63 1030 23 RA 36 OD:20/400 OS:20/100 OD:20/400 OS:20/150 Decreased central vision Decreased central vision Yes (OCT)
S2/F/76 1679 19 RA 14 OD:20/150 OS:20/50 OD:20/100 OS:20/100 Blurry vision Blurry vision No
  1. E2 left eye was included in Severe group analysis. E3 right eye was included in Obvious group analysis
  2. aInformation unavailable